Endometriosis and Endometriosis-Associated Ovarian Cancer (EAOC)

Endometriosis is a gynecologic disease that affects over 10% of women of reproductive age causing pelvic pain, dysmenorrhea, and infertility, resulting in significant disability and reduced quality of life. Very recent genetic studies have suggested that endometriosis is a clonal disease in the epithelium and its development is independent of stroma, providing new insight into the genesis of endometriosis. The endometrioid tissue lining may also react by epithelial atypical hyperplasia and even neoplasia, in a manner somehow similar to that in the uterine cavity and under the same hormonal influences. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others

Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin N Am. 1997;24(2):235–58. Lim MC, et al. Clinical presentation of endometrioid epithelial ovarian cancer with concurrent endometriosis: a multicenter retrospective study. Cancer Epidemiol Biomark Prev. 2010;19(2):398–404. JA S. Endometrial carcinoma of ovary arising in endometrial tissue in that organ. Arch Surg. 1925;10:1–72. Kajiyama H, et al. Endometriosis and cancer. Free Radic Biol Med. 2019;133:186–92. Brinton LA, et al. Causes of infertility as predictors of subsequent cancer risk. Epidemiology. 2005;16(4):500–7. Melin A, et al. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod. 2006;21(5):1237–42. Melin A, Sparen P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Hum Reprod. 2007;22(11):3021–6. Olson JE, et al. Postmenopausal cancer risk after self-reported endometriosis diagnosis in the Iowa Women’s Health study. Cancer. 2002;94(5):1612–8. Kondi-Pafiti A, et al. Clinicopathological characteristics of ovarian carcinomas associated with endometriosis. Arch Gynecol Obstet. 2012;285(2):479–83. Van Gorp T, et al. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol. 2004;18(2):349–71. Brinton LA, et al. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997;176(3):572–9. Valenzuela P, et al. Endometrioid adenocarcinoma of the ovary and endometriosis. Eur J Obstet Gynecol Reprod Biol. 2007;134(1):83–6. Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol. 1990;75(6):1023–8. Benoit L, et al. Malignant extraovarian endometriosis: a review. Eur J Surg Oncol. 2006;32(1):6–11. Modesitt SC, et al. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol. 2002;100(4):788–95. Ness RB, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000;11(2):111–7. Ness RB, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002;155(3):217–24. Vigano P, et al. Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. Fertil Steril. 2007;88(3):588–93. Borgfeldt C, Andolf E. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand. 2004;83(4):395–400. Brinton LA, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril. 2004;82(2):405–14. Modugno F, et al. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004;191(3):733–40. Kobayashi H, et al. Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer. 2007;17(1):37–43. Pearce CL, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385–94. Ozerlat I. Gynecological cancer: Endometriosis link to invasive subtypes. Nat Rev Clin Oncol. 2012;9(4):189. Wei JJ, William J, Bulun S. Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynecol Pathol. 2011;30(6):553–68. Deligdisch L, et al. Stage I ovarian carcinoma: different clinical pathologic patterns. Fertil Steril. 2007;88(4):906–10. Zou Y, et al. The presence of KRAS, PPP2R1A and ARID1A mutations in 101 Chinese samples with ovarian endometriosis. Mutat Res. 2018;809:1–5. Takeda T, et al. ARID1A gene mutation in ovarian and endometrial cancers (review). Oncol Rep. 2016;35(2):607–13. Ishikawa M, et al. Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients. Oncotarget. 2018;9(19):14754–63. Nezhat F, et al. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer. 2002;94(11):2935–40. Anglesio MS, et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med. 2017;376(19):1835–48. Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol. 2012;124(1):164–9. Wiegand KC, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–43. Kobayashi H, et al. Integrating modern approaches to pathogenetic concepts of malignant transformation of endometriosis. Oncol Rep. 2019;41(3):1729–38. Bukulmez O, et al. Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology. 2008;149(3):1190–204. Rambau P, et al. Association of hormone receptor expression with survival in ovarian endometrioid carcinoma: biological validation and clinical implications. Int J Mol Sci. 2017;18(3):515. Yamaguchi K, et al. Epigenetic determinants of ovarian clear cell carcinoma biology. Int J Cancer. 2014;135(3):585–97. Kobayashi H, et al. Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma. Oncol Lett. 2015;10(2):612–8. Jana S, et al. Regulation of matrix metalloproteinase-2 activity by COX-2-PGE2-pAKT axis promotes angiogenesis in endometriosis. PLoS One. 2016;11(10):e0163540. Del Carmen MG, et al. Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer. 2003;98(8):1658–63. Nezhat F, et al. Clinical and histologic classification of endometriomas. Implications for a mechanism of pathogenesis. J Reprod Med. 1992;37(9):771–6. Melin AS, et al. Hormonal and surgical treatments for endometriosis and risk of epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2013;92(5):546–54. Nezhat FR, et al. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 2015;213(3):262–7. Nezhat F, et al. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril. 2008;90(5):1559–70. Nezhat CH, et al. Laparoscopic management of 15 patients with infiltrating endometriosis of the bladder and a case of primary intravesical endometrioid adenosarcoma. Fertil Steril. 2002;78(4):872–5. Mangili G, Bergamini A, Taccagni G, Gentile C, Panina P, Viganò P, et al. Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience. Gynecol Oncol. 2012 Sep;126(3):403–7. Schultheis AM, et al. Massively parallel sequencing-based Clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. J Natl Cancer Inst. 2016;108(6):djv427. Deligdisch L, et al. Stage I ovarian carcinoma: different clinical pathologic patterns. Fert Stert. 2006;88(4):906–10. Walsh, et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005 Oct;106(4):693–9. Anglesio MS, et al. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol. 2015;236:201–9. Garavaglia, et al. The origin of endometriosis-associated ovarian cancer from uterine neoplastic lesions. Med Hypoth. 2018;110:80–2. Matias-Guiu X, Stewart CJ. Endometriosis-associated ovarian neoplasia. Pathology. 2018;50(2):190–204. Yu HC, et al. Increased association between endometriosis and endometrial cancer. A nationwide population based retrospective cohort study. Int J Gynecol Cancer. 2015;25(3):447–52. Poole EM, et al. Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses. Cancer Causes Control. 2017;28(5):437–45. Worley MJ, et al. Endometriosis associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14:5367–79. Barreta A, et al. Endometriosis associated ovarian cancer: population characteristics and prognosis. Int J Gynecol Cancer. 2018;28(7):1251–7. Noli S, et al. Long term survival of ovarian endometriosis associated clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer. 2013;23(2):244–8. Nagar H, et al. Adjuvant pelvic radiation therapy +/− vaginal brachytherapy in patients with high risk stage I or stage II uterine papillary serous, clear cell, and high-grade endometrioid carcinoma. Am J Clin Oncol. 2016;39(4):335–9. Davis M, et al. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol. 2014;132(2):760–6. Paik ES, et al. Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. J Gynecol Oncol. 2018;29(2):e18. Sahin H, et al. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma? Arch Gynecol Obstet. 2018;297(4):1005–13. Bell J, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paciltaxel in early stage epithelial ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2006;102(3):432–9. Chan JK, et al. The potential benefit of 6 vs 3 cycles of chemotherapy in subsets of women with early stage high risk epithelial ovarian cancer: an exploratory analysis of a gynecologic oncology group study. Gynecol Oncol. 2010;116(3):301–6. Takano M, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Brit J Cancer. 2006;94(10):1369–74. Shu CA, et al. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. Gynecol Oncol. 2015;139(2):236–41. Sugiyama T, et al. Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG trial. J Clin Oncol. 2016;34(24):2881–7. Nagai Y, et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol. 2007;107:469–73. Swenerton KD, et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Onc. 2010;22(2):341–7. Hoskins PJ, et al. Low stage ovarian clear cell carcinoma: population based outcomes in British Columbia Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol. 2012;30(14):1656–62. Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception. 2004;69(6):469–76. Witjes H, Creinin MD, Sundström-Poromaa I, Martin Nguyen A, Korver T. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea. Eur J Contracept Reprod Health Care. 2015;20(4):296–307. Muzii L, Di Tucci C, Achilli C, et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016;214(2):203–11. Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107(3):533–6. Staubhar A, et al. Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone. Gynecol Oncol Rep. 2017;10(21):10–2. Jerzak K, et al. Endocrine therapy in endometrial cancer: an old dog with new tricks. Gynecol Oncol. 2019;153(1):175–83. Pedernea E, Gomora M, Morales-Vasquez F, Perez-Montiel D, Mendez C. Progesterone reduces cell survival in primary culture of endometrioid ovarian carcinoma. J Ovarian Res. 2019;12(1):15–22. Bowman A, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine sensitive subgroup. Clin Cancer Res. 2002;8:2233–9. Papadimitriou CA, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long term results of a phase II study. Oncology. 2004;66:112–7. Smyth JF, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor positive patients. Clin Cancer Res. 2007;13:3617–22. Ramirez PT, et al. Efficacy of letrozole in the treatment of recurrent platinum and taxane resistant high grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008;110:56–9. Zhao D, et al. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. In J Gynecol Cancer. 2013;23(1):25–33. Modungo F, et al. Contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004;191(3):733–44. Author information Authors and Affiliations Corresponding author Editor information Editors and Affiliations Rights and permissions Copyright information © 2020 Springer Nature Switzerland AG About this chapter Cite this chapter Pejovic, T., Thisted, S., White, M., Nezhat, F.R. (2020). Endometriosis and Endometriosis-Associated Ovarian Cancer (EAOC). In: Deligdisch-Schor, L., Mareş Miceli, A. (eds) Hormonal Pathology of the Uterus . Advances in Experimental Medicine and Biology, vol 1242. Springer, Cham. https://doi.org/10.1007/978-3-030-38474-6_5 Download citation DOI: https://doi.org/10.1007/978-3-030-38474-6_5 Published: Publisher Name: Springer, Cham Print ISBN: 978-3-030-38473-9 Online ISBN: 978-3-030-38474-6 eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)